PMCID	SUBJECT_SCOPE_ID	S_START	S_END	SUBJECT_SCOPE	CONCEPT	IGNORANCE TYPE	C_START	C_END	CONCEPT_MENTION_ID
PMC1481554	PMC1481554_0	[0]	[339]	['A randomized cross over trial of tolerability and compliance of a micronutrient supplement with low iron separated from calcium vs high iron combined with calcium in pregnant women [ISRCTN56071145]\n\nAbstract\n\nBackground\nPrenatal micronutrient combinations with high iron content are associated with high rates of gastrointestinal symptoms.']	micronutrient	CHEBI_EXT	[66]	[79]	PMC1481554_T0
PMC1481554	PMC1481554_0	[0]	[339]	['A randomized cross over trial of tolerability and compliance of a micronutrient supplement with low iron separated from calcium vs high iron combined with calcium in pregnant women [ISRCTN56071145]\n\nAbstract\n\nBackground\nPrenatal micronutrient combinations with high iron content are associated with high rates of gastrointestinal symptoms.']	iron	CHEBI_EXT	[100]	[104]	PMC1481554_T1
PMC1481554	PMC1481554_0	[0]	[339]	['A randomized cross over trial of tolerability and compliance of a micronutrient supplement with low iron separated from calcium vs high iron combined with calcium in pregnant women [ISRCTN56071145]\n\nAbstract\n\nBackground\nPrenatal micronutrient combinations with high iron content are associated with high rates of gastrointestinal symptoms.']	calcium	CHEBI_EXT	[120]	[127]	PMC1481554_T2
PMC1481554	PMC1481554_0	[0]	[339]	['A randomized cross over trial of tolerability and compliance of a micronutrient supplement with low iron separated from calcium vs high iron combined with calcium in pregnant women [ISRCTN56071145]\n\nAbstract\n\nBackground\nPrenatal micronutrient combinations with high iron content are associated with high rates of gastrointestinal symptoms.']	iron	CHEBI_EXT	[136]	[140]	PMC1481554_T3
PMC1481554	PMC1481554_0	[0]	[339]	['A randomized cross over trial of tolerability and compliance of a micronutrient supplement with low iron separated from calcium vs high iron combined with calcium in pregnant women [ISRCTN56071145]\n\nAbstract\n\nBackground\nPrenatal micronutrient combinations with high iron content are associated with high rates of gastrointestinal symptoms.']	calcium	CHEBI_EXT	[155]	[162]	PMC1481554_T4
PMC1481554	PMC1481554_0	[0]	[339]	['A randomized cross over trial of tolerability and compliance of a micronutrient supplement with low iron separated from calcium vs high iron combined with calcium in pregnant women [ISRCTN56071145]\n\nAbstract\n\nBackground\nPrenatal micronutrient combinations with high iron content are associated with high rates of gastrointestinal symptoms.']	pregnant	GO_BP_EXT	[166]	[174]	PMC1481554_T153
PMC1481554	PMC1481554_0	[0]	[339]	['A randomized cross over trial of tolerability and compliance of a micronutrient supplement with low iron separated from calcium vs high iron combined with calcium in pregnant women [ISRCTN56071145]\n\nAbstract\n\nBackground\nPrenatal micronutrient combinations with high iron content are associated with high rates of gastrointestinal symptoms.']	women	NCBITAXON_EXT	[175]	[180]	PMC1481554_T197
PMC1481554	PMC1481554_0	[0]	[339]	['A randomized cross over trial of tolerability and compliance of a micronutrient supplement with low iron separated from calcium vs high iron combined with calcium in pregnant women [ISRCTN56071145]\n\nAbstract\n\nBackground\nPrenatal micronutrient combinations with high iron content are associated with high rates of gastrointestinal symptoms.']	Prenatal	GO_BP_EXT	[220]	[228]	PMC1481554_T154
PMC1481554	PMC1481554_0	[0]	[339]	['A randomized cross over trial of tolerability and compliance of a micronutrient supplement with low iron separated from calcium vs high iron combined with calcium in pregnant women [ISRCTN56071145]\n\nAbstract\n\nBackground\nPrenatal micronutrient combinations with high iron content are associated with high rates of gastrointestinal symptoms.']	micronutrient	CHEBI_EXT	[229]	[242]	PMC1481554_T5
PMC1481554	PMC1481554_0	[0]	[339]	['A randomized cross over trial of tolerability and compliance of a micronutrient supplement with low iron separated from calcium vs high iron combined with calcium in pregnant women [ISRCTN56071145]\n\nAbstract\n\nBackground\nPrenatal micronutrient combinations with high iron content are associated with high rates of gastrointestinal symptoms.']	iron	CHEBI_EXT	[266]	[270]	PMC1481554_T6
PMC1481554	PMC1481554_0	[0]	[339]	['A randomized cross over trial of tolerability and compliance of a micronutrient supplement with low iron separated from calcium vs high iron combined with calcium in pregnant women [ISRCTN56071145]\n\nAbstract\n\nBackground\nPrenatal micronutrient combinations with high iron content are associated with high rates of gastrointestinal symptoms.']	gastrointestinal	UBERON_EXT	[313]	[329]	PMC1481554_T221
PMC1481554	PMC1481554_1	[340]	[448]	['This coupled with nausea and vomiting of pregnancy results in women often discontinuing their multivitamins.']	pregnancy	GO_BP_EXT	[381]	[390]	PMC1481554_T155
PMC1481554	PMC1481554_1	[340]	[448]	['This coupled with nausea and vomiting of pregnancy results in women often discontinuing their multivitamins.']	women	NCBITAXON_EXT	[402]	[407]	PMC1481554_T198
PMC1481554	PMC1481554_1	[340]	[448]	['This coupled with nausea and vomiting of pregnancy results in women often discontinuing their multivitamins.']	multivitamins	CHEBI_EXT	[434]	[447]	PMC1481554_T7
PMC1481554	PMC1481554_2	[449]	[736]	['A new prescription supplement (PregVit®) that separates iron from calcium in two tablets – morning and evening, has lower elemental iron content (35 mg), but results in similar extent of iron absorption when compared to another supplement containing (60 mg) of elemental iron (Materna®).']	iron	CHEBI_EXT	[505]	[509]	PMC1481554_T8
PMC1481554	PMC1481554_2	[449]	[736]	['A new prescription supplement (PregVit®) that separates iron from calcium in two tablets – morning and evening, has lower elemental iron content (35 mg), but results in similar extent of iron absorption when compared to another supplement containing (60 mg) of elemental iron (Materna®).']	calcium	CHEBI_EXT	[515]	[522]	PMC1481554_T9
PMC1481554	PMC1481554_2	[449]	[736]	['A new prescription supplement (PregVit®) that separates iron from calcium in two tablets – morning and evening, has lower elemental iron content (35 mg), but results in similar extent of iron absorption when compared to another supplement containing (60 mg) of elemental iron (Materna®).']	iron	CHEBI_EXT	[581]	[585]	PMC1481554_T10
PMC1481554	PMC1481554_2	[449]	[736]	['A new prescription supplement (PregVit®) that separates iron from calcium in two tablets – morning and evening, has lower elemental iron content (35 mg), but results in similar extent of iron absorption when compared to another supplement containing (60 mg) of elemental iron (Materna®).']	iron	CHEBI_EXT	[636]	[640]	PMC1481554_T11
PMC1481554	PMC1481554_2	[449]	[736]	['A new prescription supplement (PregVit®) that separates iron from calcium in two tablets – morning and evening, has lower elemental iron content (35 mg), but results in similar extent of iron absorption when compared to another supplement containing (60 mg) of elemental iron (Materna®).']	iron	CHEBI_EXT	[720]	[724]	PMC1481554_T12
PMC1481554	PMC1481554_4	[827]	[893]	['a supplement with high iron content (Materna®), in pregnant women.']	iron	CHEBI_EXT	[850]	[854]	PMC1481554_T13
PMC1481554	PMC1481554_4	[827]	[893]	['a supplement with high iron content (Materna®), in pregnant women.']	pregnant	GO_BP_EXT	[878]	[886]	PMC1481554_T156
PMC1481554	PMC1481554_4	[827]	[893]	['a supplement with high iron content (Materna®), in pregnant women.']	women	NCBITAXON_EXT	[887]	[892]	PMC1481554_T199
PMC1481554	PMC1481554_5	[895]	[1017]	['Methods\nRandomized, crossover open labeled study in 135 pregnant women attending outpatient clinics in Ontario and Quebec.']	pregnant	GO_BP_EXT	[951]	[959]	PMC1481554_T157
PMC1481554	PMC1481554_5	[895]	[1017]	['Methods\nRandomized, crossover open labeled study in 135 pregnant women attending outpatient clinics in Ontario and Quebec.']	pregnant	UBERON_EXT	[951]	[959]	PMC1481554_T222
PMC1481554	PMC1481554_5	[895]	[1017]	['Methods\nRandomized, crossover open labeled study in 135 pregnant women attending outpatient clinics in Ontario and Quebec.']	women	NCBITAXON_EXT	[960]	[965]	PMC1481554_T200
PMC1481554	PMC1481554_5	[895]	[1017]	['Methods\nRandomized, crossover open labeled study in 135 pregnant women attending outpatient clinics in Ontario and Quebec.']	women	UBERON_EXT	[960]	[965]	PMC1481554_T223
PMC1481554	PMC1481554_8	[1177]	[1279]	['Compliance of Materna®was negatively associated with the severity of nausea and vomiting of pregnancy.']	pregnancy	GO_BP_EXT	[1269]	[1278]	PMC1481554_T158
PMC1481554	PMC1481554_10	[1326]	[1508]	['Conclusion\nPregVit®, a supplement with lower iron content (35 mg), has significantly decreased constipation rates as compared to 60 mg iron- Materna and has similar compliance rates.']	iron	CHEBI_EXT	[1371]	[1375]	PMC1481554_T14
PMC1481554	PMC1481554_10	[1326]	[1508]	['Conclusion\nPregVit®, a supplement with lower iron content (35 mg), has significantly decreased constipation rates as compared to 60 mg iron- Materna and has similar compliance rates.']	iron	CHEBI_EXT	[1461]	[1465]	PMC1481554_T15
PMC1481554	PMC1481554_11	[1509]	[1603]	['High iron content in multivitamin supplements is associated with adverse effects in pregnancy.']	iron	CHEBI_EXT	[1514]	[1518]	PMC1481554_T16
PMC1481554	PMC1481554_11	[1509]	[1603]	['High iron content in multivitamin supplements is associated with adverse effects in pregnancy.']	multivitamin	CHEBI_EXT	[1530]	[1542]	PMC1481554_T17
PMC1481554	PMC1481554_11	[1509]	[1603]	['High iron content in multivitamin supplements is associated with adverse effects in pregnancy.']	pregnancy	GO_BP_EXT	[1593]	[1602]	PMC1481554_T159
PMC1481554	PMC1481554_12	[1605]	[1832]	['Background\nPrenatal micronutrient supplementation is indicated for all pregnant women, because the recommended daily allowances (RDA) for many vitamins and minerals are not met during pregnancy with dietary sources alone [1,2].']	Prenatal	GO_BP_EXT	[1616]	[1624]	PMC1481554_T160
PMC1481554	PMC1481554_12	[1605]	[1832]	['Background\nPrenatal micronutrient supplementation is indicated for all pregnant women, because the recommended daily allowances (RDA) for many vitamins and minerals are not met during pregnancy with dietary sources alone [1,2].']	micronutrient	CHEBI_EXT	[1625]	[1638]	PMC1481554_T18
PMC1481554	PMC1481554_12	[1605]	[1832]	['Background\nPrenatal micronutrient supplementation is indicated for all pregnant women, because the recommended daily allowances (RDA) for many vitamins and minerals are not met during pregnancy with dietary sources alone [1,2].']	pregnant	GO_BP_EXT	[1676]	[1684]	PMC1481554_T161
PMC1481554	PMC1481554_12	[1605]	[1832]	['Background\nPrenatal micronutrient supplementation is indicated for all pregnant women, because the recommended daily allowances (RDA) for many vitamins and minerals are not met during pregnancy with dietary sources alone [1,2].']	women	NCBITAXON_EXT	[1685]	[1690]	PMC1481554_T201
PMC1481554	PMC1481554_12	[1605]	[1832]	['Background\nPrenatal micronutrient supplementation is indicated for all pregnant women, because the recommended daily allowances (RDA) for many vitamins and minerals are not met during pregnancy with dietary sources alone [1,2].']	vitamins	CHEBI_EXT	[1748]	[1756]	PMC1481554_T19
PMC1481554	PMC1481554_12	[1605]	[1832]	['Background\nPrenatal micronutrient supplementation is indicated for all pregnant women, because the recommended daily allowances (RDA) for many vitamins and minerals are not met during pregnancy with dietary sources alone [1,2].']	minerals	CHEBI_EXT	[1761]	[1769]	PMC1481554_T20
PMC1481554	PMC1481554_12	[1605]	[1832]	['Background\nPrenatal micronutrient supplementation is indicated for all pregnant women, because the recommended daily allowances (RDA) for many vitamins and minerals are not met during pregnancy with dietary sources alone [1,2].']	pregnancy	GO_BP_EXT	[1789]	[1798]	PMC1481554_T162
PMC1481554	PMC1481554_13	[1833]	[1943]	["Prior to 1990's, physicians typically commenced prenatal micronutrients at the time of diagnosis of pregnancy."]	prenatal	GO_BP_EXT	[1881]	[1889]	PMC1481554_T163
PMC1481554	PMC1481554_13	[1833]	[1943]	["Prior to 1990's, physicians typically commenced prenatal micronutrients at the time of diagnosis of pregnancy."]	micronutrients	CHEBI_EXT	[1890]	[1904]	PMC1481554_T21
PMC1481554	PMC1481554_13	[1833]	[1943]	["Prior to 1990's, physicians typically commenced prenatal micronutrients at the time of diagnosis of pregnancy."]	pregnancy	GO_BP_EXT	[1933]	[1942]	PMC1481554_T164
PMC1481554	PMC1481554_14	[1944]	[2143]	['However, proving the ability of folic acid supplementation to prevent neural tube defects, has led to the recommendation to start prenatal micronutrient supplementation when planning pregnancy [3,4].']	folic acid	CHEBI_EXT	[1976]	[1986]	PMC1481554_T22
PMC1481554	PMC1481554_14	[1944]	[2143]	['However, proving the ability of folic acid supplementation to prevent neural tube defects, has led to the recommendation to start prenatal micronutrient supplementation when planning pregnancy [3,4].']	neural tube	UBERON_EXT	[2014]	[2025]	PMC1481554_T224
PMC1481554	PMC1481554_14	[1944]	[2143]	['However, proving the ability of folic acid supplementation to prevent neural tube defects, has led to the recommendation to start prenatal micronutrient supplementation when planning pregnancy [3,4].']	prenatal	GO_BP_EXT	[2074]	[2082]	PMC1481554_T165
PMC1481554	PMC1481554_14	[1944]	[2143]	['However, proving the ability of folic acid supplementation to prevent neural tube defects, has led to the recommendation to start prenatal micronutrient supplementation when planning pregnancy [3,4].']	micronutrient	CHEBI_EXT	[2083]	[2096]	PMC1481554_T23
PMC1481554	PMC1481554_14	[1944]	[2143]	['However, proving the ability of folic acid supplementation to prevent neural tube defects, has led to the recommendation to start prenatal micronutrient supplementation when planning pregnancy [3,4].']	pregnancy	GO_BP_EXT	[2127]	[2136]	PMC1481554_T166
PMC1481554	PMC1481554_15	[2144]	[2313]	['A recent analysis has further documented the importance of micronutrient supplementation during pregnancy in preventing malformations other than neural tube defects [5].']	micronutrient	CHEBI_EXT	[2203]	[2216]	PMC1481554_T24
PMC1481554	PMC1481554_15	[2144]	[2313]	['A recent analysis has further documented the importance of micronutrient supplementation during pregnancy in preventing malformations other than neural tube defects [5].']	pregnancy	GO_BP_EXT	[2240]	[2249]	PMC1481554_T167
PMC1481554	PMC1481554_15	[2144]	[2313]	['A recent analysis has further documented the importance of micronutrient supplementation during pregnancy in preventing malformations other than neural tube defects [5].']	neural tube	UBERON_EXT	[2289]	[2300]	PMC1481554_T225
PMC1481554	PMC1481554_16	[2314]	[2549]	['The findings are consistent with the notion that periconceptional multivitamin use, containing folic acid, reduces the overall occurrence of birth defects by 15–33%, in addition to the demonstrated reduction in neural tube defects [6].']	folic acid	CHEBI_EXT	[2409]	[2419]	PMC1481554_T25
PMC1481554	PMC1481554_16	[2314]	[2549]	['The findings are consistent with the notion that periconceptional multivitamin use, containing folic acid, reduces the overall occurrence of birth defects by 15–33%, in addition to the demonstrated reduction in neural tube defects [6].']	birth	GO_BP_EXT	[2455]	[2460]	PMC1481554_T168
PMC1481554	PMC1481554_16	[2314]	[2549]	['The findings are consistent with the notion that periconceptional multivitamin use, containing folic acid, reduces the overall occurrence of birth defects by 15–33%, in addition to the demonstrated reduction in neural tube defects [6].']	neural tube	UBERON_EXT	[2525]	[2536]	PMC1481554_T226
PMC1481554	PMC1481554_17	[2550]	[2718]	['Typically, many prenatal supplements contain, among other minerals, elemental iron at 50–60 mg, to prevent pregnancy-induced anemia secondary to increasing fetal needs.']	prenatal	GO_BP_EXT	[2566]	[2574]	PMC1481554_T169
PMC1481554	PMC1481554_17	[2550]	[2718]	['Typically, many prenatal supplements contain, among other minerals, elemental iron at 50–60 mg, to prevent pregnancy-induced anemia secondary to increasing fetal needs.']	minerals	CHEBI_EXT	[2608]	[2616]	PMC1481554_T26
PMC1481554	PMC1481554_17	[2550]	[2718]	['Typically, many prenatal supplements contain, among other minerals, elemental iron at 50–60 mg, to prevent pregnancy-induced anemia secondary to increasing fetal needs.']	iron	CHEBI_EXT	[2628]	[2632]	PMC1481554_T27
PMC1481554	PMC1481554_17	[2550]	[2718]	['Typically, many prenatal supplements contain, among other minerals, elemental iron at 50–60 mg, to prevent pregnancy-induced anemia secondary to increasing fetal needs.']	pregnancy	GO_BP_EXT	[2657]	[2666]	PMC1481554_T170
PMC1481554	PMC1481554_18	[2719]	[2853]	['However, this level of iron content has been associated adverse gastrointestinal effects, including nausea, vomiting and constipation.']	iron	CHEBI_EXT	[2742]	[2746]	PMC1481554_T28
PMC1481554	PMC1481554_18	[2719]	[2853]	['However, this level of iron content has been associated adverse gastrointestinal effects, including nausea, vomiting and constipation.']	gastrointestinal	UBERON_EXT	[2783]	[2799]	PMC1481554_T227
PMC1481554	PMC1481554_19	[2854]	[3016]	['The common occurrence of nausea and vomiting of pregnancy (NVP) has further led women to discontinue prenatal supplementation containing these levels of iron [7].']	pregnancy	GO_BP_EXT	[2902]	[2911]	PMC1481554_T171
PMC1481554	PMC1481554_19	[2854]	[3016]	['The common occurrence of nausea and vomiting of pregnancy (NVP) has further led women to discontinue prenatal supplementation containing these levels of iron [7].']	NVP	CHEBI_EXT	[2913]	[2916]	PMC1481554_T29
PMC1481554	PMC1481554_19	[2854]	[3016]	['The common occurrence of nausea and vomiting of pregnancy (NVP) has further led women to discontinue prenatal supplementation containing these levels of iron [7].']	women	NCBITAXON_EXT	[2934]	[2939]	PMC1481554_T202
PMC1481554	PMC1481554_19	[2854]	[3016]	['The common occurrence of nausea and vomiting of pregnancy (NVP) has further led women to discontinue prenatal supplementation containing these levels of iron [7].']	prenatal	GO_BP_EXT	[2955]	[2963]	PMC1481554_T172
PMC1481554	PMC1481554_19	[2854]	[3016]	['The common occurrence of nausea and vomiting of pregnancy (NVP) has further led women to discontinue prenatal supplementation containing these levels of iron [7].']	iron	CHEBI_EXT	[3007]	[3011]	PMC1481554_T30
PMC1481554	PMC1481554_20	[3017]	[3267]	['A new prescription prenatal micronutrient supplement PregVit®has recently been introduced into the Canadian Market aiming to address these issues: PregVit®, taken twice daily, contains less elemental iron (35 mg) than many other prenatal supplements.']	prenatal	GO_BP_EXT	[3036]	[3044]	PMC1481554_T173
PMC1481554	PMC1481554_20	[3017]	[3267]	['A new prescription prenatal micronutrient supplement PregVit®has recently been introduced into the Canadian Market aiming to address these issues: PregVit®, taken twice daily, contains less elemental iron (35 mg) than many other prenatal supplements.']	micronutrient	CHEBI_EXT	[3045]	[3058]	PMC1481554_T31
PMC1481554	PMC1481554_20	[3017]	[3267]	['A new prescription prenatal micronutrient supplement PregVit®has recently been introduced into the Canadian Market aiming to address these issues: PregVit®, taken twice daily, contains less elemental iron (35 mg) than many other prenatal supplements.']	iron	CHEBI_EXT	[3217]	[3221]	PMC1481554_T32
PMC1481554	PMC1481554_20	[3017]	[3267]	['A new prescription prenatal micronutrient supplement PregVit®has recently been introduced into the Canadian Market aiming to address these issues: PregVit®, taken twice daily, contains less elemental iron (35 mg) than many other prenatal supplements.']	prenatal	GO_BP_EXT	[3246]	[3254]	PMC1481554_T174
PMC1481554	PMC1481554_21	[3268]	[3318]	['Iron is incorporated in the morning dose (Table1).']	Iron	CHEBI_EXT	[3268]	[3272]	PMC1481554_T33
PMC1481554	PMC1481554_22	[3319]	[3446]	['The evening dose of PregVit®contains calcium, which is known to inhibit iron absorption from the gastrointestinal tract [8-11].']	calcium	CHEBI_EXT	[3356]	[3363]	PMC1481554_T34
PMC1481554	PMC1481554_22	[3319]	[3446]	['The evening dose of PregVit®contains calcium, which is known to inhibit iron absorption from the gastrointestinal tract [8-11].']	iron	CHEBI_EXT	[3391]	[3395]	PMC1481554_T35
PMC1481554	PMC1481554_22	[3319]	[3446]	['The evening dose of PregVit®contains calcium, which is known to inhibit iron absorption from the gastrointestinal tract [8-11].']	gastrointestinal tract	UBERON_EXT	[3416]	[3438]	PMC1481554_T228
PMC1481554	PMC1481554_23	[3447]	[3634]	['By separating the two elements it was hypothesized that despite a lower total iron dose – a similar systemic exposure to iron would occur as with the other high iron prenatal supplements.']	iron	CHEBI_EXT	[3525]	[3529]	PMC1481554_T36
PMC1481554	PMC1481554_23	[3447]	[3634]	['By separating the two elements it was hypothesized that despite a lower total iron dose – a similar systemic exposure to iron would occur as with the other high iron prenatal supplements.']	iron	CHEBI_EXT	[3568]	[3572]	PMC1481554_T37
PMC1481554	PMC1481554_23	[3447]	[3634]	['By separating the two elements it was hypothesized that despite a lower total iron dose – a similar systemic exposure to iron would occur as with the other high iron prenatal supplements.']	iron	CHEBI_EXT	[3608]	[3612]	PMC1481554_T38
PMC1481554	PMC1481554_23	[3447]	[3634]	['By separating the two elements it was hypothesized that despite a lower total iron dose – a similar systemic exposure to iron would occur as with the other high iron prenatal supplements.']	prenatal	GO_BP_EXT	[3613]	[3621]	PMC1481554_T175
PMC1481554	PMC1481554_24	[3635]	[3748]	['Moreover, PregVit®contains higher doses of vitamin C, which is also known to facilitate iron absorption (Table1).']	vitamin C	CHEBI_EXT	[3678]	[3687]	PMC1481554_T39
PMC1481554	PMC1481554_24	[3635]	[3748]	['Moreover, PregVit®contains higher doses of vitamin C, which is also known to facilitate iron absorption (Table1).']	iron	CHEBI_EXT	[3723]	[3727]	PMC1481554_T40
PMC1481554	PMC1481554_25	[3750]	[3951]	['Caption (TABLE-WRAP): TABLE 1\n\nComposition of two prenatal supplements and Recommended Dietary Allowance (RDA) values12ComponentPregVit®Materna®*** Recommended dietary allowance (RDA)a.m. tablet** Vit.']	prenatal	GO_BP_EXT	[3800]	[3808]	PMC1481554_T176
PMC1481554	PMC1481554_26	[3952]	[4035]	['Aψ2700 IU (β-Carotene)1500 IU (β-Carotene) 1500 IU (acetate)750–770 μg retinol Vit.']	β-Carotene	CHEBI_EXT	[3963]	[3973]	PMC1481554_T41
PMC1481554	PMC1481554_26	[3952]	[4035]	['Aψ2700 IU (β-Carotene)1500 IU (β-Carotene) 1500 IU (acetate)750–770 μg retinol Vit.']	β-Carotene	CHEBI_EXT	[3983]	[3993]	PMC1481554_T42
PMC1481554	PMC1481554_26	[3952]	[4035]	['Aψ2700 IU (β-Carotene)1500 IU (β-Carotene) 1500 IU (acetate)750–770 μg retinol Vit.']	acetate	CHEBI_EXT	[4004]	[4011]	PMC1481554_T43
PMC1481554	PMC1481554_26	[3952]	[4035]	['Aψ2700 IU (β-Carotene)1500 IU (β-Carotene) 1500 IU (acetate)750–770 μg retinol Vit.']	retinol	CHEBI_EXT	[4023]	[4030]	PMC1481554_T44
PMC1481554	PMC1481554_29	[4087]	[4118]	['B1(thiamin) 3 mg3 mg1.4 mg Vit.']	thiamin	CHEBI_EXT	[4090]	[4097]	PMC1481554_T45
PMC1481554	PMC1481554_30	[4119]	[4185]	['B2(riboflavin) 3.4 mg3.4 mg1.4 mg Niacinamide 20 mg20 mg18 mg Vit.']	Niacinamide	CHEBI_EXT	[4153]	[4164]	PMC1481554_T46
PMC1481554	PMC1481554_31	[4186]	[4416]	['B610 mg10 mg1.9 mg Pantothenic acid (calcium pantothenate) 5 mg10 mg6 mg* Magnesium 50 mg50 mg350–400 mg Iodine 0.15 mg0.15 mg0.22 mg Iron 35 mg (as fumarate)60 mg (as fumarate)27 mg Copper 2 mg2 mg1 mg Zinc 15 mg25 mg11–12 mgp.m.']	Pantothenic acid	CHEBI_EXT	[4205]	[4221]	PMC1481554_T47
PMC1481554	PMC1481554_31	[4186]	[4416]	['B610 mg10 mg1.9 mg Pantothenic acid (calcium pantothenate) 5 mg10 mg6 mg* Magnesium 50 mg50 mg350–400 mg Iodine 0.15 mg0.15 mg0.22 mg Iron 35 mg (as fumarate)60 mg (as fumarate)27 mg Copper 2 mg2 mg1 mg Zinc 15 mg25 mg11–12 mgp.m.']	calcium pantothenate	CHEBI_EXT	[4223]	[4243]	PMC1481554_T48
PMC1481554	PMC1481554_31	[4186]	[4416]	['B610 mg10 mg1.9 mg Pantothenic acid (calcium pantothenate) 5 mg10 mg6 mg* Magnesium 50 mg50 mg350–400 mg Iodine 0.15 mg0.15 mg0.22 mg Iron 35 mg (as fumarate)60 mg (as fumarate)27 mg Copper 2 mg2 mg1 mg Zinc 15 mg25 mg11–12 mgp.m.']	Magnesium	CHEBI_EXT	[4260]	[4269]	PMC1481554_T49
PMC1481554	PMC1481554_31	[4186]	[4416]	['B610 mg10 mg1.9 mg Pantothenic acid (calcium pantothenate) 5 mg10 mg6 mg* Magnesium 50 mg50 mg350–400 mg Iodine 0.15 mg0.15 mg0.22 mg Iron 35 mg (as fumarate)60 mg (as fumarate)27 mg Copper 2 mg2 mg1 mg Zinc 15 mg25 mg11–12 mgp.m.']	Iodine	CHEBI_EXT	[4291]	[4297]	PMC1481554_T50
PMC1481554	PMC1481554_31	[4186]	[4416]	['B610 mg10 mg1.9 mg Pantothenic acid (calcium pantothenate) 5 mg10 mg6 mg* Magnesium 50 mg50 mg350–400 mg Iodine 0.15 mg0.15 mg0.22 mg Iron 35 mg (as fumarate)60 mg (as fumarate)27 mg Copper 2 mg2 mg1 mg Zinc 15 mg25 mg11–12 mgp.m.']	Iron	CHEBI_EXT	[4320]	[4324]	PMC1481554_T51
PMC1481554	PMC1481554_31	[4186]	[4416]	['B610 mg10 mg1.9 mg Pantothenic acid (calcium pantothenate) 5 mg10 mg6 mg* Magnesium 50 mg50 mg350–400 mg Iodine 0.15 mg0.15 mg0.22 mg Iron 35 mg (as fumarate)60 mg (as fumarate)27 mg Copper 2 mg2 mg1 mg Zinc 15 mg25 mg11–12 mgp.m.']	fumarate	CHEBI_EXT	[4335]	[4343]	PMC1481554_T52
PMC1481554	PMC1481554_31	[4186]	[4416]	['B610 mg10 mg1.9 mg Pantothenic acid (calcium pantothenate) 5 mg10 mg6 mg* Magnesium 50 mg50 mg350–400 mg Iodine 0.15 mg0.15 mg0.22 mg Iron 35 mg (as fumarate)60 mg (as fumarate)27 mg Copper 2 mg2 mg1 mg Zinc 15 mg25 mg11–12 mgp.m.']	fumarate	CHEBI_EXT	[4354]	[4362]	PMC1481554_T53
PMC1481554	PMC1481554_31	[4186]	[4416]	['B610 mg10 mg1.9 mg Pantothenic acid (calcium pantothenate) 5 mg10 mg6 mg* Magnesium 50 mg50 mg350–400 mg Iodine 0.15 mg0.15 mg0.22 mg Iron 35 mg (as fumarate)60 mg (as fumarate)27 mg Copper 2 mg2 mg1 mg Zinc 15 mg25 mg11–12 mgp.m.']	Copper	CHEBI_EXT	[4369]	[4375]	PMC1481554_T54
PMC1481554	PMC1481554_31	[4186]	[4416]	['B610 mg10 mg1.9 mg Pantothenic acid (calcium pantothenate) 5 mg10 mg6 mg* Magnesium 50 mg50 mg350–400 mg Iodine 0.15 mg0.15 mg0.22 mg Iron 35 mg (as fumarate)60 mg (as fumarate)27 mg Copper 2 mg2 mg1 mg Zinc 15 mg25 mg11–12 mgp.m.']	Zinc	CHEBI_EXT	[4389]	[4393]	PMC1481554_T55
PMC1481554	PMC1481554_32	[4417]	[4458]	['tablet** Folic Acid 1.1 mg1 mg0.6 mg Vit.']	Folic Acid	CHEBI_EXT	[4426]	[4436]	PMC1481554_T56
PMC1481554	PMC1481554_33	[4459]	[4501]	['B12(cyanocaobalamin) 12 μg12 μg2.6 μg Vit.']	cyanocaobalamin	CHEBI_EXT	[4463]	[4478]	PMC1481554_T57
PMC1481554	PMC1481554_34	[4502]	[5361]	['D (cholecalciferol)ε250 IU250 IU5 μg* Calcium 300 mg250 mg1000–1300 mg* Biotin 030 μg- Chromium 025 μg29–30 μg* Manganese 05 mg2 mg* Molybdenum 025 μg50 μg Selenium 025 μg60 μg Pill Size Smalllarge\n* Adequate Intake\n** Applies only to PregVit®\nψVIT A – 1 International Unit (IU) of retinol is equivalent to 0.3 μg retinol (750 μg of retinol is 2,500 IU of retinol)\n2 μg of supplemental β-carotene is equivalent to 1 μg retinol3 (page 92 & 565)\nξVIT E – 1 International Unite (IU) is equivalent to 0.67 μg of α-tocopherol (15 mg is equivalent to 22,388 IU)\nHowever, different conversion factors are used for different forms of vitamin E\nε VIT D – 1 IU is equivalent to 0.025 μg of cholecalciferol (5 μg is equivalent to 200 IU)\n*** Please note : Since the completion of this study a new formulation of Materna was introduced containing 27 mg of elemental iron.']	cholecalciferol	CHEBI_EXT	[4505]	[4520]	PMC1481554_T58
PMC1481554	PMC1481554_34	[4502]	[5361]	['D (cholecalciferol)ε250 IU250 IU5 μg* Calcium 300 mg250 mg1000–1300 mg* Biotin 030 μg- Chromium 025 μg29–30 μg* Manganese 05 mg2 mg* Molybdenum 025 μg50 μg Selenium 025 μg60 μg Pill Size Smalllarge\n* Adequate Intake\n** Applies only to PregVit®\nψVIT A – 1 International Unit (IU) of retinol is equivalent to 0.3 μg retinol (750 μg of retinol is 2,500 IU of retinol)\n2 μg of supplemental β-carotene is equivalent to 1 μg retinol3 (page 92 & 565)\nξVIT E – 1 International Unite (IU) is equivalent to 0.67 μg of α-tocopherol (15 mg is equivalent to 22,388 IU)\nHowever, different conversion factors are used for different forms of vitamin E\nε VIT D – 1 IU is equivalent to 0.025 μg of cholecalciferol (5 μg is equivalent to 200 IU)\n*** Please note : Since the completion of this study a new formulation of Materna was introduced containing 27 mg of elemental iron.']	Calcium	CHEBI_EXT	[4540]	[4547]	PMC1481554_T59
PMC1481554	PMC1481554_34	[4502]	[5361]	['D (cholecalciferol)ε250 IU250 IU5 μg* Calcium 300 mg250 mg1000–1300 mg* Biotin 030 μg- Chromium 025 μg29–30 μg* Manganese 05 mg2 mg* Molybdenum 025 μg50 μg Selenium 025 μg60 μg Pill Size Smalllarge\n* Adequate Intake\n** Applies only to PregVit®\nψVIT A – 1 International Unit (IU) of retinol is equivalent to 0.3 μg retinol (750 μg of retinol is 2,500 IU of retinol)\n2 μg of supplemental β-carotene is equivalent to 1 μg retinol3 (page 92 & 565)\nξVIT E – 1 International Unite (IU) is equivalent to 0.67 μg of α-tocopherol (15 mg is equivalent to 22,388 IU)\nHowever, different conversion factors are used for different forms of vitamin E\nε VIT D – 1 IU is equivalent to 0.025 μg of cholecalciferol (5 μg is equivalent to 200 IU)\n*** Please note : Since the completion of this study a new formulation of Materna was introduced containing 27 mg of elemental iron.']	Biotin	CHEBI_EXT	[4574]	[4580]	PMC1481554_T60
PMC1481554	PMC1481554_34	[4502]	[5361]	['D (cholecalciferol)ε250 IU250 IU5 μg* Calcium 300 mg250 mg1000–1300 mg* Biotin 030 μg- Chromium 025 μg29–30 μg* Manganese 05 mg2 mg* Molybdenum 025 μg50 μg Selenium 025 μg60 μg Pill Size Smalllarge\n* Adequate Intake\n** Applies only to PregVit®\nψVIT A – 1 International Unit (IU) of retinol is equivalent to 0.3 μg retinol (750 μg of retinol is 2,500 IU of retinol)\n2 μg of supplemental β-carotene is equivalent to 1 μg retinol3 (page 92 & 565)\nξVIT E – 1 International Unite (IU) is equivalent to 0.67 μg of α-tocopherol (15 mg is equivalent to 22,388 IU)\nHowever, different conversion factors are used for different forms of vitamin E\nε VIT D – 1 IU is equivalent to 0.025 μg of cholecalciferol (5 μg is equivalent to 200 IU)\n*** Please note : Since the completion of this study a new formulation of Materna was introduced containing 27 mg of elemental iron.']	Chromium	CHEBI_EXT	[4589]	[4597]	PMC1481554_T61
PMC1481554	PMC1481554_34	[4502]	[5361]	['D (cholecalciferol)ε250 IU250 IU5 μg* Calcium 300 mg250 mg1000–1300 mg* Biotin 030 μg- Chromium 025 μg29–30 μg* Manganese 05 mg2 mg* Molybdenum 025 μg50 μg Selenium 025 μg60 μg Pill Size Smalllarge\n* Adequate Intake\n** Applies only to PregVit®\nψVIT A – 1 International Unit (IU) of retinol is equivalent to 0.3 μg retinol (750 μg of retinol is 2,500 IU of retinol)\n2 μg of supplemental β-carotene is equivalent to 1 μg retinol3 (page 92 & 565)\nξVIT E – 1 International Unite (IU) is equivalent to 0.67 μg of α-tocopherol (15 mg is equivalent to 22,388 IU)\nHowever, different conversion factors are used for different forms of vitamin E\nε VIT D – 1 IU is equivalent to 0.025 μg of cholecalciferol (5 μg is equivalent to 200 IU)\n*** Please note : Since the completion of this study a new formulation of Materna was introduced containing 27 mg of elemental iron.']	Manganese	CHEBI_EXT	[4614]	[4623]	PMC1481554_T62
PMC1481554	PMC1481554_34	[4502]	[5361]	['D (cholecalciferol)ε250 IU250 IU5 μg* Calcium 300 mg250 mg1000–1300 mg* Biotin 030 μg- Chromium 025 μg29–30 μg* Manganese 05 mg2 mg* Molybdenum 025 μg50 μg Selenium 025 μg60 μg Pill Size Smalllarge\n* Adequate Intake\n** Applies only to PregVit®\nψVIT A – 1 International Unit (IU) of retinol is equivalent to 0.3 μg retinol (750 μg of retinol is 2,500 IU of retinol)\n2 μg of supplemental β-carotene is equivalent to 1 μg retinol3 (page 92 & 565)\nξVIT E – 1 International Unite (IU) is equivalent to 0.67 μg of α-tocopherol (15 mg is equivalent to 22,388 IU)\nHowever, different conversion factors are used for different forms of vitamin E\nε VIT D – 1 IU is equivalent to 0.025 μg of cholecalciferol (5 μg is equivalent to 200 IU)\n*** Please note : Since the completion of this study a new formulation of Materna was introduced containing 27 mg of elemental iron.']	Molybdenum	CHEBI_EXT	[4635]	[4645]	PMC1481554_T63
PMC1481554	PMC1481554_34	[4502]	[5361]	['D (cholecalciferol)ε250 IU250 IU5 μg* Calcium 300 mg250 mg1000–1300 mg* Biotin 030 μg- Chromium 025 μg29–30 μg* Manganese 05 mg2 mg* Molybdenum 025 μg50 μg Selenium 025 μg60 μg Pill Size Smalllarge\n* Adequate Intake\n** Applies only to PregVit®\nψVIT A – 1 International Unit (IU) of retinol is equivalent to 0.3 μg retinol (750 μg of retinol is 2,500 IU of retinol)\n2 μg of supplemental β-carotene is equivalent to 1 μg retinol3 (page 92 & 565)\nξVIT E – 1 International Unite (IU) is equivalent to 0.67 μg of α-tocopherol (15 mg is equivalent to 22,388 IU)\nHowever, different conversion factors are used for different forms of vitamin E\nε VIT D – 1 IU is equivalent to 0.025 μg of cholecalciferol (5 μg is equivalent to 200 IU)\n*** Please note : Since the completion of this study a new formulation of Materna was introduced containing 27 mg of elemental iron.']	Molybdenum	UBERON_EXT	[4635]	[4645]	PMC1481554_T229
PMC1481554	PMC1481554_34	[4502]	[5361]	['D (cholecalciferol)ε250 IU250 IU5 μg* Calcium 300 mg250 mg1000–1300 mg* Biotin 030 μg- Chromium 025 μg29–30 μg* Manganese 05 mg2 mg* Molybdenum 025 μg50 μg Selenium 025 μg60 μg Pill Size Smalllarge\n* Adequate Intake\n** Applies only to PregVit®\nψVIT A – 1 International Unit (IU) of retinol is equivalent to 0.3 μg retinol (750 μg of retinol is 2,500 IU of retinol)\n2 μg of supplemental β-carotene is equivalent to 1 μg retinol3 (page 92 & 565)\nξVIT E – 1 International Unite (IU) is equivalent to 0.67 μg of α-tocopherol (15 mg is equivalent to 22,388 IU)\nHowever, different conversion factors are used for different forms of vitamin E\nε VIT D – 1 IU is equivalent to 0.025 μg of cholecalciferol (5 μg is equivalent to 200 IU)\n*** Please note : Since the completion of this study a new formulation of Materna was introduced containing 27 mg of elemental iron.']	Selenium	CHEBI_EXT	[4658]	[4666]	PMC1481554_T64
PMC1481554	PMC1481554_34	[4502]	[5361]	['D (cholecalciferol)ε250 IU250 IU5 μg* Calcium 300 mg250 mg1000–1300 mg* Biotin 030 μg- Chromium 025 μg29–30 μg* Manganese 05 mg2 mg* Molybdenum 025 μg50 μg Selenium 025 μg60 μg Pill Size Smalllarge\n* Adequate Intake\n** Applies only to PregVit®\nψVIT A – 1 International Unit (IU) of retinol is equivalent to 0.3 μg retinol (750 μg of retinol is 2,500 IU of retinol)\n2 μg of supplemental β-carotene is equivalent to 1 μg retinol3 (page 92 & 565)\nξVIT E – 1 International Unite (IU) is equivalent to 0.67 μg of α-tocopherol (15 mg is equivalent to 22,388 IU)\nHowever, different conversion factors are used for different forms of vitamin E\nε VIT D – 1 IU is equivalent to 0.025 μg of cholecalciferol (5 μg is equivalent to 200 IU)\n*** Please note : Since the completion of this study a new formulation of Materna was introduced containing 27 mg of elemental iron.']	retinol	CHEBI_EXT	[4784]	[4791]	PMC1481554_T65
PMC1481554	PMC1481554_34	[4502]	[5361]	['D (cholecalciferol)ε250 IU250 IU5 μg* Calcium 300 mg250 mg1000–1300 mg* Biotin 030 μg- Chromium 025 μg29–30 μg* Manganese 05 mg2 mg* Molybdenum 025 μg50 μg Selenium 025 μg60 μg Pill Size Smalllarge\n* Adequate Intake\n** Applies only to PregVit®\nψVIT A – 1 International Unit (IU) of retinol is equivalent to 0.3 μg retinol (750 μg of retinol is 2,500 IU of retinol)\n2 μg of supplemental β-carotene is equivalent to 1 μg retinol3 (page 92 & 565)\nξVIT E – 1 International Unite (IU) is equivalent to 0.67 μg of α-tocopherol (15 mg is equivalent to 22,388 IU)\nHowever, different conversion factors are used for different forms of vitamin E\nε VIT D – 1 IU is equivalent to 0.025 μg of cholecalciferol (5 μg is equivalent to 200 IU)\n*** Please note : Since the completion of this study a new formulation of Materna was introduced containing 27 mg of elemental iron.']	retinol	CHEBI_EXT	[4816]	[4823]	PMC1481554_T66
PMC1481554	PMC1481554_34	[4502]	[5361]	['D (cholecalciferol)ε250 IU250 IU5 μg* Calcium 300 mg250 mg1000–1300 mg* Biotin 030 μg- Chromium 025 μg29–30 μg* Manganese 05 mg2 mg* Molybdenum 025 μg50 μg Selenium 025 μg60 μg Pill Size Smalllarge\n* Adequate Intake\n** Applies only to PregVit®\nψVIT A – 1 International Unit (IU) of retinol is equivalent to 0.3 μg retinol (750 μg of retinol is 2,500 IU of retinol)\n2 μg of supplemental β-carotene is equivalent to 1 μg retinol3 (page 92 & 565)\nξVIT E – 1 International Unite (IU) is equivalent to 0.67 μg of α-tocopherol (15 mg is equivalent to 22,388 IU)\nHowever, different conversion factors are used for different forms of vitamin E\nε VIT D – 1 IU is equivalent to 0.025 μg of cholecalciferol (5 μg is equivalent to 200 IU)\n*** Please note : Since the completion of this study a new formulation of Materna was introduced containing 27 mg of elemental iron.']	retinol	CHEBI_EXT	[4835]	[4842]	PMC1481554_T67
PMC1481554	PMC1481554_34	[4502]	[5361]	['D (cholecalciferol)ε250 IU250 IU5 μg* Calcium 300 mg250 mg1000–1300 mg* Biotin 030 μg- Chromium 025 μg29–30 μg* Manganese 05 mg2 mg* Molybdenum 025 μg50 μg Selenium 025 μg60 μg Pill Size Smalllarge\n* Adequate Intake\n** Applies only to PregVit®\nψVIT A – 1 International Unit (IU) of retinol is equivalent to 0.3 μg retinol (750 μg of retinol is 2,500 IU of retinol)\n2 μg of supplemental β-carotene is equivalent to 1 μg retinol3 (page 92 & 565)\nξVIT E – 1 International Unite (IU) is equivalent to 0.67 μg of α-tocopherol (15 mg is equivalent to 22,388 IU)\nHowever, different conversion factors are used for different forms of vitamin E\nε VIT D – 1 IU is equivalent to 0.025 μg of cholecalciferol (5 μg is equivalent to 200 IU)\n*** Please note : Since the completion of this study a new formulation of Materna was introduced containing 27 mg of elemental iron.']	retinol	CHEBI_EXT	[4858]	[4865]	PMC1481554_T68
PMC1481554	PMC1481554_34	[4502]	[5361]	['D (cholecalciferol)ε250 IU250 IU5 μg* Calcium 300 mg250 mg1000–1300 mg* Biotin 030 μg- Chromium 025 μg29–30 μg* Manganese 05 mg2 mg* Molybdenum 025 μg50 μg Selenium 025 μg60 μg Pill Size Smalllarge\n* Adequate Intake\n** Applies only to PregVit®\nψVIT A – 1 International Unit (IU) of retinol is equivalent to 0.3 μg retinol (750 μg of retinol is 2,500 IU of retinol)\n2 μg of supplemental β-carotene is equivalent to 1 μg retinol3 (page 92 & 565)\nξVIT E – 1 International Unite (IU) is equivalent to 0.67 μg of α-tocopherol (15 mg is equivalent to 22,388 IU)\nHowever, different conversion factors are used for different forms of vitamin E\nε VIT D – 1 IU is equivalent to 0.025 μg of cholecalciferol (5 μg is equivalent to 200 IU)\n*** Please note : Since the completion of this study a new formulation of Materna was introduced containing 27 mg of elemental iron.']	carotene	CHEBI_EXT	[4890]	[4898]	PMC1481554_T69
PMC1481554	PMC1481554_34	[4502]	[5361]	['D (cholecalciferol)ε250 IU250 IU5 μg* Calcium 300 mg250 mg1000–1300 mg* Biotin 030 μg- Chromium 025 μg29–30 μg* Manganese 05 mg2 mg* Molybdenum 025 μg50 μg Selenium 025 μg60 μg Pill Size Smalllarge\n* Adequate Intake\n** Applies only to PregVit®\nψVIT A – 1 International Unit (IU) of retinol is equivalent to 0.3 μg retinol (750 μg of retinol is 2,500 IU of retinol)\n2 μg of supplemental β-carotene is equivalent to 1 μg retinol3 (page 92 & 565)\nξVIT E – 1 International Unite (IU) is equivalent to 0.67 μg of α-tocopherol (15 mg is equivalent to 22,388 IU)\nHowever, different conversion factors are used for different forms of vitamin E\nε VIT D – 1 IU is equivalent to 0.025 μg of cholecalciferol (5 μg is equivalent to 200 IU)\n*** Please note : Since the completion of this study a new formulation of Materna was introduced containing 27 mg of elemental iron.']	retinol3	CHEBI_EXT	[4921]	[4929]	PMC1481554_T70
PMC1481554	PMC1481554_34	[4502]	[5361]	['D (cholecalciferol)ε250 IU250 IU5 μg* Calcium 300 mg250 mg1000–1300 mg* Biotin 030 μg- Chromium 025 μg29–30 μg* Manganese 05 mg2 mg* Molybdenum 025 μg50 μg Selenium 025 μg60 μg Pill Size Smalllarge\n* Adequate Intake\n** Applies only to PregVit®\nψVIT A – 1 International Unit (IU) of retinol is equivalent to 0.3 μg retinol (750 μg of retinol is 2,500 IU of retinol)\n2 μg of supplemental β-carotene is equivalent to 1 μg retinol3 (page 92 & 565)\nξVIT E – 1 International Unite (IU) is equivalent to 0.67 μg of α-tocopherol (15 mg is equivalent to 22,388 IU)\nHowever, different conversion factors are used for different forms of vitamin E\nε VIT D – 1 IU is equivalent to 0.025 μg of cholecalciferol (5 μg is equivalent to 200 IU)\n*** Please note : Since the completion of this study a new formulation of Materna was introduced containing 27 mg of elemental iron.']	α-tocopherol	CHEBI_EXT	[5010]	[5022]	PMC1481554_T71
PMC1481554	PMC1481554_34	[4502]	[5361]	['D (cholecalciferol)ε250 IU250 IU5 μg* Calcium 300 mg250 mg1000–1300 mg* Biotin 030 μg- Chromium 025 μg29–30 μg* Manganese 05 mg2 mg* Molybdenum 025 μg50 μg Selenium 025 μg60 μg Pill Size Smalllarge\n* Adequate Intake\n** Applies only to PregVit®\nψVIT A – 1 International Unit (IU) of retinol is equivalent to 0.3 μg retinol (750 μg of retinol is 2,500 IU of retinol)\n2 μg of supplemental β-carotene is equivalent to 1 μg retinol3 (page 92 & 565)\nξVIT E – 1 International Unite (IU) is equivalent to 0.67 μg of α-tocopherol (15 mg is equivalent to 22,388 IU)\nHowever, different conversion factors are used for different forms of vitamin E\nε VIT D – 1 IU is equivalent to 0.025 μg of cholecalciferol (5 μg is equivalent to 200 IU)\n*** Please note : Since the completion of this study a new formulation of Materna was introduced containing 27 mg of elemental iron.']	vitamin E	CHEBI_EXT	[5128]	[5137]	PMC1481554_T72
PMC1481554	PMC1481554_34	[4502]	[5361]	['D (cholecalciferol)ε250 IU250 IU5 μg* Calcium 300 mg250 mg1000–1300 mg* Biotin 030 μg- Chromium 025 μg29–30 μg* Manganese 05 mg2 mg* Molybdenum 025 μg50 μg Selenium 025 μg60 μg Pill Size Smalllarge\n* Adequate Intake\n** Applies only to PregVit®\nψVIT A – 1 International Unit (IU) of retinol is equivalent to 0.3 μg retinol (750 μg of retinol is 2,500 IU of retinol)\n2 μg of supplemental β-carotene is equivalent to 1 μg retinol3 (page 92 & 565)\nξVIT E – 1 International Unite (IU) is equivalent to 0.67 μg of α-tocopherol (15 mg is equivalent to 22,388 IU)\nHowever, different conversion factors are used for different forms of vitamin E\nε VIT D – 1 IU is equivalent to 0.025 μg of cholecalciferol (5 μg is equivalent to 200 IU)\n*** Please note : Since the completion of this study a new formulation of Materna was introduced containing 27 mg of elemental iron.']	vitamin E	PR_EXT	[5128]	[5137]	PMC1481554_T218
PMC1481554	PMC1481554_34	[4502]	[5361]	['D (cholecalciferol)ε250 IU250 IU5 μg* Calcium 300 mg250 mg1000–1300 mg* Biotin 030 μg- Chromium 025 μg29–30 μg* Manganese 05 mg2 mg* Molybdenum 025 μg50 μg Selenium 025 μg60 μg Pill Size Smalllarge\n* Adequate Intake\n** Applies only to PregVit®\nψVIT A – 1 International Unit (IU) of retinol is equivalent to 0.3 μg retinol (750 μg of retinol is 2,500 IU of retinol)\n2 μg of supplemental β-carotene is equivalent to 1 μg retinol3 (page 92 & 565)\nξVIT E – 1 International Unite (IU) is equivalent to 0.67 μg of α-tocopherol (15 mg is equivalent to 22,388 IU)\nHowever, different conversion factors are used for different forms of vitamin E\nε VIT D – 1 IU is equivalent to 0.025 μg of cholecalciferol (5 μg is equivalent to 200 IU)\n*** Please note : Since the completion of this study a new formulation of Materna was introduced containing 27 mg of elemental iron.']	cholecalciferol	CHEBI_EXT	[5182]	[5197]	PMC1481554_T73
PMC1481554	PMC1481554_34	[4502]	[5361]	['D (cholecalciferol)ε250 IU250 IU5 μg* Calcium 300 mg250 mg1000–1300 mg* Biotin 030 μg- Chromium 025 μg29–30 μg* Manganese 05 mg2 mg* Molybdenum 025 μg50 μg Selenium 025 μg60 μg Pill Size Smalllarge\n* Adequate Intake\n** Applies only to PregVit®\nψVIT A – 1 International Unit (IU) of retinol is equivalent to 0.3 μg retinol (750 μg of retinol is 2,500 IU of retinol)\n2 μg of supplemental β-carotene is equivalent to 1 μg retinol3 (page 92 & 565)\nξVIT E – 1 International Unite (IU) is equivalent to 0.67 μg of α-tocopherol (15 mg is equivalent to 22,388 IU)\nHowever, different conversion factors are used for different forms of vitamin E\nε VIT D – 1 IU is equivalent to 0.025 μg of cholecalciferol (5 μg is equivalent to 200 IU)\n*** Please note : Since the completion of this study a new formulation of Materna was introduced containing 27 mg of elemental iron.']	iron	CHEBI_EXT	[5356]	[5360]	PMC1481554_T74
PMC1481554	PMC1481554_35	[5362]	[5603]	['A recent pharmacokinetic study has shown that the extent of iron absorption with PregVit®(in terms of area under the concentration-time curve) was similar to that of Materna®, despite PregVit®containing only about half of the iron dose [12].']	iron	CHEBI_EXT	[5422]	[5426]	PMC1481554_T75
PMC1481554	PMC1481554_35	[5362]	[5603]	['A recent pharmacokinetic study has shown that the extent of iron absorption with PregVit®(in terms of area under the concentration-time curve) was similar to that of Materna®, despite PregVit®containing only about half of the iron dose [12].']	iron	CHEBI_EXT	[5588]	[5592]	PMC1481554_T76
PMC1481554	PMC1481554_36	[5604]	[5728]	['The objective of the present study was to compare tolerability and compliance with PregVit®and Materna®among pregnant women.']	pregnant	GO_BP_EXT	[5713]	[5721]	PMC1481554_T177
PMC1481554	PMC1481554_36	[5604]	[5728]	['The objective of the present study was to compare tolerability and compliance with PregVit®and Materna®among pregnant women.']	women	NCBITAXON_EXT	[5722]	[5727]	PMC1481554_T203
PMC1481554	PMC1481554_37	[5730]	[6006]	['Methods\nApproval of the study protocol was obtained from the local ethics committee at The Hospital for Sick Children, in Toronto, Ontario, the North York General Hospital (NYGH) in Toronto, Ontario and the Clinique de Gynécologie-Obstétrique Pierre Boucher (CGOPB) in Quebec.']	Children	NCBITAXON_EXT	[5839]	[5847]	PMC1481554_T204
PMC1481554	PMC1481554_37	[5730]	[6006]	['Methods\nApproval of the study protocol was obtained from the local ethics committee at The Hospital for Sick Children, in Toronto, Ontario, the North York General Hospital (NYGH) in Toronto, Ontario and the Clinique de Gynécologie-Obstétrique Pierre Boucher (CGOPB) in Quebec.']	Children	UBERON_EXT	[5839]	[5847]	PMC1481554_T230
PMC1481554	PMC1481554_39	[6167]	[6274]	['Participants were eligible to enroll in the study if they were pregnant and between 18 and 45 years of age.']	pregnant	GO_BP_EXT	[6230]	[6238]	PMC1481554_T178
PMC1481554	PMC1481554_41	[6343]	[6481]	['Between June 2003 and November 2003, women attending out patients obstetric clinics at NYGH and CGOPB were invited to enroll in the study.']	women	NCBITAXON_EXT	[6380]	[6385]	PMC1481554_T205
PMC1481554	PMC1481554_41	[6343]	[6481]	['Between June 2003 and November 2003, women attending out patients obstetric clinics at NYGH and CGOPB were invited to enroll in the study.']	women	UBERON_EXT	[6380]	[6385]	PMC1481554_T231
PMC1481554	PMC1481554_41	[6343]	[6481]	['Between June 2003 and November 2003, women attending out patients obstetric clinics at NYGH and CGOPB were invited to enroll in the study.']	obstetric	UBERON_EXT	[6409]	[6418]	PMC1481554_T232
PMC1481554	PMC1481554_43	[6604]	[6805]	['Participating women were asked to complete a standardized questionnaire recording demographic data, pregnancy and, medical history, drug and vitamin use and information on their normal bowel movements.']	women	NCBITAXON_EXT	[6618]	[6623]	PMC1481554_T206
PMC1481554	PMC1481554_43	[6604]	[6805]	['Participating women were asked to complete a standardized questionnaire recording demographic data, pregnancy and, medical history, drug and vitamin use and information on their normal bowel movements.']	women	UBERON_EXT	[6618]	[6623]	PMC1481554_T233
PMC1481554	PMC1481554_43	[6604]	[6805]	['Participating women were asked to complete a standardized questionnaire recording demographic data, pregnancy and, medical history, drug and vitamin use and information on their normal bowel movements.']	pregnancy	GO_BP_EXT	[6704]	[6713]	PMC1481554_T179
PMC1481554	PMC1481554_43	[6604]	[6805]	['Participating women were asked to complete a standardized questionnaire recording demographic data, pregnancy and, medical history, drug and vitamin use and information on their normal bowel movements.']	drug	CHEBI_EXT	[6736]	[6740]	PMC1481554_T77
PMC1481554	PMC1481554_43	[6604]	[6805]	['Participating women were asked to complete a standardized questionnaire recording demographic data, pregnancy and, medical history, drug and vitamin use and information on their normal bowel movements.']	vitamin	CHEBI_EXT	[6745]	[6752]	PMC1481554_T78
PMC1481554	PMC1481554_43	[6604]	[6805]	['Participating women were asked to complete a standardized questionnaire recording demographic data, pregnancy and, medical history, drug and vitamin use and information on their normal bowel movements.']	bowel	UBERON_EXT	[6789]	[6794]	PMC1481554_T234
PMC1481554	PMC1481554_43	[6604]	[6805]	['Participating women were asked to complete a standardized questionnaire recording demographic data, pregnancy and, medical history, drug and vitamin use and information on their normal bowel movements.']	movements	GO_BP_EXT	[6795]	[6804]	PMC1481554_T180
PMC1481554	PMC1481554_44	[6806]	[6935]	['Based on the existence of NVP, participants were block-randomized to receive either Materna®or PregVit®to be taken for one month.']	NVP	CHEBI_EXT	[6832]	[6835]	PMC1481554_T79
PMC1481554	PMC1481554_45	[6936]	[7085]	['The block randomization aimed at ensuring similar numbers of women with NVP/no NVP receiving each of the products first as NVP may affect compliance.']	women	NCBITAXON_EXT	[6997]	[7002]	PMC1481554_T207
PMC1481554	PMC1481554_45	[6936]	[7085]	['The block randomization aimed at ensuring similar numbers of women with NVP/no NVP receiving each of the products first as NVP may affect compliance.']	women	UBERON_EXT	[6997]	[7002]	PMC1481554_T235
PMC1481554	PMC1481554_45	[6936]	[7085]	['The block randomization aimed at ensuring similar numbers of women with NVP/no NVP receiving each of the products first as NVP may affect compliance.']	NVP	CHEBI_EXT	[7008]	[7011]	PMC1481554_T80
PMC1481554	PMC1481554_45	[6936]	[7085]	['The block randomization aimed at ensuring similar numbers of women with NVP/no NVP receiving each of the products first as NVP may affect compliance.']	NVP	CHEBI_EXT	[7015]	[7018]	PMC1481554_T81
PMC1481554	PMC1481554_45	[6936]	[7085]	['The block randomization aimed at ensuring similar numbers of women with NVP/no NVP receiving each of the products first as NVP may affect compliance.']	NVP	CHEBI_EXT	[7059]	[7062]	PMC1481554_T82
PMC1481554	PMC1481554_48	[7183]	[7310]	['The severity of their NVP was monitored by the Pregnancy-Unique Questionnaire of Emesis and nausea (PUQE) scores (Table2) [13].']	NVP	CHEBI_EXT	[7205]	[7208]	PMC1481554_T83
PMC1481554	PMC1481554_48	[7183]	[7310]	['The severity of their NVP was monitored by the Pregnancy-Unique Questionnaire of Emesis and nausea (PUQE) scores (Table2) [13].']	Pregnancy	GO_BP_EXT	[7230]	[7239]	PMC1481554_T181
PMC1481554	PMC1481554_48	[7183]	[7310]	['The severity of their NVP was monitored by the Pregnancy-Unique Questionnaire of Emesis and nausea (PUQE) scores (Table2) [13].']	Emesis	GO_BP_EXT	[7264]	[7270]	PMC1481554_T182
PMC1481554	PMC1481554_49	[7311]	[7433]	['In addition, changes in diet as well as the use of medications and adherence to the study drug were recorded in the diary.']	medications	CHEBI_EXT	[7362]	[7373]	PMC1481554_T84
PMC1481554	PMC1481554_49	[7311]	[7433]	['In addition, changes in diet as well as the use of medications and adherence to the study drug were recorded in the diary.']	drug	CHEBI_EXT	[7401]	[7405]	PMC1481554_T85
PMC1481554	PMC1481554_52	[7631]	[7764]	['The women were then given the alternative product and were asked to record the same information in the diary for the following month.']	women	NCBITAXON_EXT	[7635]	[7640]	PMC1481554_T208
PMC1481554	PMC1481554_52	[7631]	[7764]	['The women were then given the alternative product and were asked to record the same information in the diary for the following month.']	women	UBERON_EXT	[7635]	[7640]	PMC1481554_T236
PMC1481554	PMC1481554_53	[7765]	[7898]	['Upon completion of the two month cross over, participants were asked to return their diaries and supplement bottles for a pill count.']	supplement	CHEBI_EXT	[7862]	[7872]	PMC1481554_T86
PMC1481554	PMC1481554_55	[7952]	[8071]	['Patients were asked to circle the appropriate box next to the three symptoms of nausea and vomiting of pregnancy (NVP).']	pregnancy	GO_BP_EXT	[8055]	[8064]	PMC1481554_T183
PMC1481554	PMC1481554_55	[7952]	[8071]	['Patients were asked to circle the appropriate box next to the three symptoms of nausea and vomiting of pregnancy (NVP).']	NVP	CHEBI_EXT	[8066]	[8069]	PMC1481554_T87
PMC1481554	PMC1481554_57	[8125]	[8192]	['The total score is calculated and determines the severity of NVP14.']	NVP14	PR_EXT	[8186]	[8191]	PMC1481554_T219
PMC1481554	PMC1481554_59	[8232]	[8274]	['A score of 7 to 12 indicates Moderate NVP.']	NVP	CHEBI_EXT	[8270]	[8273]	PMC1481554_T88
PMC1481554	PMC1481554_60	[8275]	[8988]	['Finally a score of 13 and greater represents Severe NVP.12345QUESTION 1 In the last 12 hours, how long have you felt nauseated or sick at your stomach ?Not at all1 hour or less2–3 hours4–6 hoursMore than 6 hours (Please specify number of hours) QUESTION 2 In the last 12 hours, have you vomited or thrown up ?I did not throw up1–2 times3–4 times5–6 times7 or more times (Please specify number of times) QUESTION 3 In the last 12 hours, how many times have you had retching or dry heaves without bringing anything up?No Time1–2 times3–4 times5–6 times7 or more (Please specify number of times)\nBefore starting the study, a pilot sample of 10 adult volunteers was tested for the feasibility of completing the diary.']	NVP	CHEBI_EXT	[8327]	[8330]	PMC1481554_T89
PMC1481554	PMC1481554_60	[8275]	[8988]	['Finally a score of 13 and greater represents Severe NVP.12345QUESTION 1 In the last 12 hours, how long have you felt nauseated or sick at your stomach ?Not at all1 hour or less2–3 hours4–6 hoursMore than 6 hours (Please specify number of hours) QUESTION 2 In the last 12 hours, have you vomited or thrown up ?I did not throw up1–2 times3–4 times5–6 times7 or more times (Please specify number of times) QUESTION 3 In the last 12 hours, how many times have you had retching or dry heaves without bringing anything up?No Time1–2 times3–4 times5–6 times7 or more (Please specify number of times)\nBefore starting the study, a pilot sample of 10 adult volunteers was tested for the feasibility of completing the diary.']	vomited	GO_BP_EXT	[8562]	[8569]	PMC1481554_T184
PMC1481554	PMC1481554_60	[8275]	[8988]	['Finally a score of 13 and greater represents Severe NVP.12345QUESTION 1 In the last 12 hours, how long have you felt nauseated or sick at your stomach ?Not at all1 hour or less2–3 hours4–6 hoursMore than 6 hours (Please specify number of hours) QUESTION 2 In the last 12 hours, have you vomited or thrown up ?I did not throw up1–2 times3–4 times5–6 times7 or more times (Please specify number of times) QUESTION 3 In the last 12 hours, how many times have you had retching or dry heaves without bringing anything up?No Time1–2 times3–4 times5–6 times7 or more (Please specify number of times)\nBefore starting the study, a pilot sample of 10 adult volunteers was tested for the feasibility of completing the diary.']	adult	UBERON_EXT	[8916]	[8921]	PMC1481554_T237
PMC1481554	PMC1481554_65	[9507]	[9743]	['Other variables such as mean days of experiencing adverse drug event (ADE), nausea, constipation and other ADE, excluding nausea and constipation, (labeled as other ), were also compared using the same statistical tests, as appropriate.']	drug	CHEBI_EXT	[9565]	[9569]	PMC1481554_T90
PMC1481554	PMC1481554_68	[9974]	[10111]	['Subsequently, multilinear regression analysis was conducted to elucidate determinants that affected compliance rate with the study drugs.']	drugs	CHEBI_EXT	[10105]	[10110]	PMC1481554_T91
PMC1481554	PMC1481554_70	[10218]	[10333]	['Rates of constipation were the primary end point of interest, as high iron content is known to induce constipation.']	iron	CHEBI_EXT	[10288]	[10292]	PMC1481554_T92
PMC1481554	PMC1481554_73	[10543]	[10674]	['Of these 109 patients, 37 patients with NVP and 45 Non NVP patients completed both arms of the study, totaling 82 patients (75.2%).']	NVP	CHEBI_EXT	[10583]	[10586]	PMC1481554_T93
PMC1481554	PMC1481554_73	[10543]	[10674]	['Of these 109 patients, 37 patients with NVP and 45 Non NVP patients completed both arms of the study, totaling 82 patients (75.2%).']	NVP	CHEBI_EXT	[10598]	[10601]	PMC1481554_T94
PMC1481554	PMC1481554_76	[10946]	[11000]	['The mean gestational age at the start was 8 ± 2 weeks.']	gestational	GO_BP_EXT	[10955]	[10966]	PMC1481554_T185
PMC1481554	PMC1481554_77	[11001]	[11062]	['There was identical gestational age at start in the two arms.']	gestational	GO_BP_EXT	[11021]	[11032]	PMC1481554_T186
PMC1481554	PMC1481554_78	[11063]	[11233]	['The women who dropped out from the study almost entirely due to the fact that they did not return for follow-up or did not fill out diaries on returning the pill bottles.']	women	NCBITAXON_EXT	[11067]	[11072]	PMC1481554_T209
PMC1481554	PMC1481554_78	[11063]	[11233]	['The women who dropped out from the study almost entirely due to the fact that they did not return for follow-up or did not fill out diaries on returning the pill bottles.']	women	UBERON_EXT	[11067]	[11072]	PMC1481554_T238
PMC1481554	PMC1481554_82	[11637]	[11794]	['Caption (TABLE-WRAP): TABLE 3\n\nOverall study results, comparing Pregvit®(low iron) to Materna®(high iron) over a month administration in a cross-over design.']	iron	CHEBI_EXT	[11714]	[11718]	PMC1481554_T95
PMC1481554	PMC1481554_82	[11637]	[11794]	['Caption (TABLE-WRAP): TABLE 3\n\nOverall study results, comparing Pregvit®(low iron) to Materna®(high iron) over a month administration in a cross-over design.']	iron	CHEBI_EXT	[11737]	[11741]	PMC1481554_T96
PMC1481554	PMC1481554_85	[12411]	[12622]	['The factors tested included: age, education, province, marital status, weight, NVP severity, any substance used such as illicit drugs and multivitamin supplement (which multivitamin they started the trial with).']	NVP	CHEBI_EXT	[12490]	[12493]	PMC1481554_T97
PMC1481554	PMC1481554_85	[12411]	[12622]	['The factors tested included: age, education, province, marital status, weight, NVP severity, any substance used such as illicit drugs and multivitamin supplement (which multivitamin they started the trial with).']	substance	CHEBI_EXT	[12508]	[12517]	PMC1481554_T98
PMC1481554	PMC1481554_85	[12411]	[12622]	['The factors tested included: age, education, province, marital status, weight, NVP severity, any substance used such as illicit drugs and multivitamin supplement (which multivitamin they started the trial with).']	illicit drugs	CHEBI_EXT	[12531]	[12544]	PMC1481554_T99
PMC1481554	PMC1481554_85	[12411]	[12622]	['The factors tested included: age, education, province, marital status, weight, NVP severity, any substance used such as illicit drugs and multivitamin supplement (which multivitamin they started the trial with).']	multivitamin	CHEBI_EXT	[12549]	[12561]	PMC1481554_T100
PMC1481554	PMC1481554_85	[12411]	[12622]	['The factors tested included: age, education, province, marital status, weight, NVP severity, any substance used such as illicit drugs and multivitamin supplement (which multivitamin they started the trial with).']	multivitamin	CHEBI_EXT	[12580]	[12592]	PMC1481554_T101
PMC1481554	PMC1481554_89	[12874]	[13577]	['Caption (TABLE-WRAP): TABLE 4\n\nMultiple linear regression of factors affecting compliance in both treatment arms.Independent VariableCoefficientStandard Errorp value Age0.000.0020.43Education-0.010.0110.58Province0.040.0260.17Marital Status-0.020.0280.43Weight0.000.0000.14NVP Severity-0.020.0120.08Substance use*0.000.0360.79Multivitamin Supplement-0.010.0190.75\n* alcohol, tobacco or illicit drugs\nFinally, multiple linear regression with patients and their reported compliance while taking Materna®revealed that marital status and NVP severity predicted their reported compliance; single motherhood predicted higher compliance rates whereas more severe NVP predicted a lower compliance rate (Table5).']	alcohol	CHEBI_EXT	[13240]	[13247]	PMC1481554_T102
PMC1481554	PMC1481554_89	[12874]	[13577]	['Caption (TABLE-WRAP): TABLE 4\n\nMultiple linear regression of factors affecting compliance in both treatment arms.Independent VariableCoefficientStandard Errorp value Age0.000.0020.43Education-0.010.0110.58Province0.040.0260.17Marital Status-0.020.0280.43Weight0.000.0000.14NVP Severity-0.020.0120.08Substance use*0.000.0360.79Multivitamin Supplement-0.010.0190.75\n* alcohol, tobacco or illicit drugs\nFinally, multiple linear regression with patients and their reported compliance while taking Materna®revealed that marital status and NVP severity predicted their reported compliance; single motherhood predicted higher compliance rates whereas more severe NVP predicted a lower compliance rate (Table5).']	tobacco	CHEBI_EXT	[13249]	[13256]	PMC1481554_T103
PMC1481554	PMC1481554_89	[12874]	[13577]	['Caption (TABLE-WRAP): TABLE 4\n\nMultiple linear regression of factors affecting compliance in both treatment arms.Independent VariableCoefficientStandard Errorp value Age0.000.0020.43Education-0.010.0110.58Province0.040.0260.17Marital Status-0.020.0280.43Weight0.000.0000.14NVP Severity-0.020.0120.08Substance use*0.000.0360.79Multivitamin Supplement-0.010.0190.75\n* alcohol, tobacco or illicit drugs\nFinally, multiple linear regression with patients and their reported compliance while taking Materna®revealed that marital status and NVP severity predicted their reported compliance; single motherhood predicted higher compliance rates whereas more severe NVP predicted a lower compliance rate (Table5).']	illicit drugs	CHEBI_EXT	[13260]	[13273]	PMC1481554_T104
PMC1481554	PMC1481554_89	[12874]	[13577]	['Caption (TABLE-WRAP): TABLE 4\n\nMultiple linear regression of factors affecting compliance in both treatment arms.Independent VariableCoefficientStandard Errorp value Age0.000.0020.43Education-0.010.0110.58Province0.040.0260.17Marital Status-0.020.0280.43Weight0.000.0000.14NVP Severity-0.020.0120.08Substance use*0.000.0360.79Multivitamin Supplement-0.010.0190.75\n* alcohol, tobacco or illicit drugs\nFinally, multiple linear regression with patients and their reported compliance while taking Materna®revealed that marital status and NVP severity predicted their reported compliance; single motherhood predicted higher compliance rates whereas more severe NVP predicted a lower compliance rate (Table5).']	NVP	CHEBI_EXT	[13408]	[13411]	PMC1481554_T105
PMC1481554	PMC1481554_89	[12874]	[13577]	['Caption (TABLE-WRAP): TABLE 4\n\nMultiple linear regression of factors affecting compliance in both treatment arms.Independent VariableCoefficientStandard Errorp value Age0.000.0020.43Education-0.010.0110.58Province0.040.0260.17Marital Status-0.020.0280.43Weight0.000.0000.14NVP Severity-0.020.0120.08Substance use*0.000.0360.79Multivitamin Supplement-0.010.0190.75\n* alcohol, tobacco or illicit drugs\nFinally, multiple linear regression with patients and their reported compliance while taking Materna®revealed that marital status and NVP severity predicted their reported compliance; single motherhood predicted higher compliance rates whereas more severe NVP predicted a lower compliance rate (Table5).']	NVP	CHEBI_EXT	[13530]	[13533]	PMC1481554_T106
PMC1481554	PMC1481554_91	[13626]	[14031]	['Caption (TABLE-WRAP): TABLE 5\n\nMultiple linear regression of compliance in patients while taking Materna®Independent VariableCoefficientStandard Errorp value Age0.000.0020.73Education-0.020.0140.09Province0.030.0310.37Race0.020.0100.11Marital Status-0.080.0340.02Weight0.000.0000.14NVP Severity*-0.050.0140.002Substance**-0.060.0440.20\n* More severe NVP was associated with significantly lower compliance.']	NVP	CHEBI_EXT	[13976]	[13979]	PMC1481554_T107
PMC1481554	PMC1481554_92	[14032]	[14148]	['No such effect was found with Pregvit®, which is a substantially smaller tablet, containing much lower iron content.']	iron	CHEBI_EXT	[14135]	[14139]	PMC1481554_T108
PMC1481554	PMC1481554_93	[14149]	[14310]	['** alcohol, tobacco or illicit drugs\n\nDiscussion\nThe results of this study demonstrate that pregnant women may experience less constipation when taking PregVit®.']	alcohol	CHEBI_EXT	[14152]	[14159]	PMC1481554_T109
PMC1481554	PMC1481554_93	[14149]	[14310]	['** alcohol, tobacco or illicit drugs\n\nDiscussion\nThe results of this study demonstrate that pregnant women may experience less constipation when taking PregVit®.']	illicit drugs	CHEBI_EXT	[14172]	[14185]	PMC1481554_T110
PMC1481554	PMC1481554_93	[14149]	[14310]	['** alcohol, tobacco or illicit drugs\n\nDiscussion\nThe results of this study demonstrate that pregnant women may experience less constipation when taking PregVit®.']	pregnant	GO_BP_EXT	[14241]	[14249]	PMC1481554_T187
PMC1481554	PMC1481554_93	[14149]	[14310]	['** alcohol, tobacco or illicit drugs\n\nDiscussion\nThe results of this study demonstrate that pregnant women may experience less constipation when taking PregVit®.']	women	NCBITAXON_EXT	[14250]	[14255]	PMC1481554_T210
PMC1481554	PMC1481554_93	[14149]	[14310]	['** alcohol, tobacco or illicit drugs\n\nDiscussion\nThe results of this study demonstrate that pregnant women may experience less constipation when taking PregVit®.']	women	UBERON_EXT	[14250]	[14255]	PMC1481554_T239
PMC1481554	PMC1481554_94	[14311]	[14452]	['These results are likely attributed to the lower iron dose contained in PregVit®relative to Materna®(35 mg and 60 mg, respectively) (Table1).']	iron	CHEBI_EXT	[14360]	[14364]	PMC1481554_T111
PMC1481554	PMC1481554_95	[14453]	[14571]	['The other differences in micronutrient content between the two preparations are not known to affect constipation rate.']	micronutrient	CHEBI_EXT	[14478]	[14491]	PMC1481554_T112
PMC1481554	PMC1481554_96	[14572]	[14685]	['It should be noted that since the completion of this study the dose of iron in Materna®has been reduced to 27 mg.']	iron	CHEBI_EXT	[14643]	[14647]	PMC1481554_T113
PMC1481554	PMC1481554_97	[14686]	[14772]	['The reformulated Materna®has the same levels of calcium, manganese and zinc as before.']	calcium	CHEBI_EXT	[14734]	[14741]	PMC1481554_T114
PMC1481554	PMC1481554_97	[14686]	[14772]	['The reformulated Materna®has the same levels of calcium, manganese and zinc as before.']	manganese	CHEBI_EXT	[14743]	[14752]	PMC1481554_T115
PMC1481554	PMC1481554_97	[14686]	[14772]	['The reformulated Materna®has the same levels of calcium, manganese and zinc as before.']	zinc	CHEBI_EXT	[14757]	[14761]	PMC1481554_T116
PMC1481554	PMC1481554_98	[14773]	[14910]	['Thus, with lower vitamin C content than PregVit®, it is possible that the systemic absorption of iron of Materna®may be subtherapeutic14.']	vitamin C	CHEBI_EXT	[14790]	[14799]	PMC1481554_T117
PMC1481554	PMC1481554_98	[14773]	[14910]	['Thus, with lower vitamin C content than PregVit®, it is possible that the systemic absorption of iron of Materna®may be subtherapeutic14.']	C	PR_EXT	[14798]	[14799]	PMC1481554_T220
PMC1481554	PMC1481554_98	[14773]	[14910]	['Thus, with lower vitamin C content than PregVit®, it is possible that the systemic absorption of iron of Materna®may be subtherapeutic14.']	iron	CHEBI_EXT	[14870]	[14874]	PMC1481554_T118
PMC1481554	PMC1481554_99	[14911]	[15113]	['Moreover, studies have suggested an antagonistic relationship between iron and zinc and manganese, in which zinc and manganese reduce the positive effects of iron supplementation and vice versa [19,21].']	iron	CHEBI_EXT	[14981]	[14985]	PMC1481554_T119
PMC1481554	PMC1481554_99	[14911]	[15113]	['Moreover, studies have suggested an antagonistic relationship between iron and zinc and manganese, in which zinc and manganese reduce the positive effects of iron supplementation and vice versa [19,21].']	zinc	CHEBI_EXT	[14990]	[14994]	PMC1481554_T120
PMC1481554	PMC1481554_99	[14911]	[15113]	['Moreover, studies have suggested an antagonistic relationship between iron and zinc and manganese, in which zinc and manganese reduce the positive effects of iron supplementation and vice versa [19,21].']	manganese	CHEBI_EXT	[14999]	[15008]	PMC1481554_T121
PMC1481554	PMC1481554_99	[14911]	[15113]	['Moreover, studies have suggested an antagonistic relationship between iron and zinc and manganese, in which zinc and manganese reduce the positive effects of iron supplementation and vice versa [19,21].']	zinc	CHEBI_EXT	[15019]	[15023]	PMC1481554_T122
PMC1481554	PMC1481554_99	[14911]	[15113]	['Moreover, studies have suggested an antagonistic relationship between iron and zinc and manganese, in which zinc and manganese reduce the positive effects of iron supplementation and vice versa [19,21].']	manganese	CHEBI_EXT	[15028]	[15037]	PMC1481554_T123
PMC1481554	PMC1481554_99	[14911]	[15113]	['Moreover, studies have suggested an antagonistic relationship between iron and zinc and manganese, in which zinc and manganese reduce the positive effects of iron supplementation and vice versa [19,21].']	iron	CHEBI_EXT	[15069]	[15073]	PMC1481554_T124
PMC1481554	PMC1481554_100	[15114]	[15283]	['It is likely that the higher dose of zinc, found in Materna®versus PregVit®plus manganese, (which is not included in PregVit®) all interfere with the absorption of iron.']	zinc	CHEBI_EXT	[15151]	[15155]	PMC1481554_T125
PMC1481554	PMC1481554_100	[15114]	[15283]	['It is likely that the higher dose of zinc, found in Materna®versus PregVit®plus manganese, (which is not included in PregVit®) all interfere with the absorption of iron.']	manganese	CHEBI_EXT	[15194]	[15203]	PMC1481554_T126
PMC1481554	PMC1481554_100	[15114]	[15283]	['It is likely that the higher dose of zinc, found in Materna®versus PregVit®plus manganese, (which is not included in PregVit®) all interfere with the absorption of iron.']	iron	CHEBI_EXT	[15278]	[15282]	PMC1481554_T127
PMC1481554	PMC1481554_101	[15284]	[15497]	['A 1993 study(16) found that supplementation with a low daily dose (18 mg) of iron given in a prenatal supplement together with inhibitive minerals was not sufficient to cover the iron needs of most pregnant women.']	iron	CHEBI_EXT	[15361]	[15365]	PMC1481554_T128
PMC1481554	PMC1481554_101	[15284]	[15497]	['A 1993 study(16) found that supplementation with a low daily dose (18 mg) of iron given in a prenatal supplement together with inhibitive minerals was not sufficient to cover the iron needs of most pregnant women.']	prenatal	GO_BP_EXT	[15377]	[15385]	PMC1481554_T188
PMC1481554	PMC1481554_101	[15284]	[15497]	['A 1993 study(16) found that supplementation with a low daily dose (18 mg) of iron given in a prenatal supplement together with inhibitive minerals was not sufficient to cover the iron needs of most pregnant women.']	minerals	CHEBI_EXT	[15422]	[15430]	PMC1481554_T129
PMC1481554	PMC1481554_101	[15284]	[15497]	['A 1993 study(16) found that supplementation with a low daily dose (18 mg) of iron given in a prenatal supplement together with inhibitive minerals was not sufficient to cover the iron needs of most pregnant women.']	iron	CHEBI_EXT	[15463]	[15467]	PMC1481554_T130
PMC1481554	PMC1481554_101	[15284]	[15497]	['A 1993 study(16) found that supplementation with a low daily dose (18 mg) of iron given in a prenatal supplement together with inhibitive minerals was not sufficient to cover the iron needs of most pregnant women.']	pregnant	GO_BP_EXT	[15482]	[15490]	PMC1481554_T189
PMC1481554	PMC1481554_101	[15284]	[15497]	['A 1993 study(16) found that supplementation with a low daily dose (18 mg) of iron given in a prenatal supplement together with inhibitive minerals was not sufficient to cover the iron needs of most pregnant women.']	women	NCBITAXON_EXT	[15491]	[15496]	PMC1481554_T211
PMC1481554	PMC1481554_102	[15498]	[15598]	['Importantly, many prenatal supplements currently available still contain 50–60 mg of elemental iron.']	prenatal	GO_BP_EXT	[15516]	[15524]	PMC1481554_T190
PMC1481554	PMC1481554_102	[15498]	[15598]	['Importantly, many prenatal supplements currently available still contain 50–60 mg of elemental iron.']	iron	CHEBI_EXT	[15593]	[15597]	PMC1481554_T131
PMC1481554	PMC1481554_105	[15767]	[15960]	['The similar compliance may be a reflection of better tolerability with PregVit®, being partially offset by the need to take this supplement twice daily, as compared to once daily with Materna®.']	supplement	CHEBI_EXT	[15896]	[15906]	PMC1481554_T132
PMC1481554	PMC1481554_106	[15961]	[16134]	['Of potential clinical importance, the multivariate analysis revealed that compliance with Materna®was negatively related to the severity of nausea and vomiting of pregnancy.']	pregnancy	GO_BP_EXT	[16124]	[16133]	PMC1481554_T191
PMC1481554	PMC1481554_108	[16255]	[16384]	['This may be explained also by a substantially larger pill size as compared to PregVit®, in addition to the direct effect of iron.']	iron	CHEBI_EXT	[16379]	[16383]	PMC1481554_T133
PMC1481554	PMC1481554_109	[16385]	[16561]	['These findings suggest that PregVit®may confer an advantage to women suffering from NVP due to both higher tolerability because of lower iron content and a smaller tablet size.']	women	NCBITAXON_EXT	[16448]	[16453]	PMC1481554_T212
PMC1481554	PMC1481554_109	[16385]	[16561]	['These findings suggest that PregVit®may confer an advantage to women suffering from NVP due to both higher tolerability because of lower iron content and a smaller tablet size.']	women	UBERON_EXT	[16448]	[16453]	PMC1481554_T240
PMC1481554	PMC1481554_109	[16385]	[16561]	['These findings suggest that PregVit®may confer an advantage to women suffering from NVP due to both higher tolerability because of lower iron content and a smaller tablet size.']	NVP	CHEBI_EXT	[16469]	[16472]	PMC1481554_T134
PMC1481554	PMC1481554_109	[16385]	[16561]	['These findings suggest that PregVit®may confer an advantage to women suffering from NVP due to both higher tolerability because of lower iron content and a smaller tablet size.']	iron	CHEBI_EXT	[16522]	[16526]	PMC1481554_T135
PMC1481554	PMC1481554_110	[16562]	[16706]	['Because NVP can very from slight food aversion to hyperemesis gravidarum, we used a validated tool that quantifies the severity of NVP (Table2).']	NVP	CHEBI_EXT	[16570]	[16573]	PMC1481554_T136
PMC1481554	PMC1481554_110	[16562]	[16706]	['Because NVP can very from slight food aversion to hyperemesis gravidarum, we used a validated tool that quantifies the severity of NVP (Table2).']	food	CHEBI_EXT	[16595]	[16599]	PMC1481554_T137
PMC1481554	PMC1481554_110	[16562]	[16706]	['Because NVP can very from slight food aversion to hyperemesis gravidarum, we used a validated tool that quantifies the severity of NVP (Table2).']	hyperemesis	GO_BP_EXT	[16612]	[16623]	PMC1481554_T192
PMC1481554	PMC1481554_110	[16562]	[16706]	['Because NVP can very from slight food aversion to hyperemesis gravidarum, we used a validated tool that quantifies the severity of NVP (Table2).']	NVP	CHEBI_EXT	[16693]	[16696]	PMC1481554_T138
PMC1481554	PMC1481554_111	[16707]	[17014]	['Potential weaknesses of this study are that the participation in this cross over protocol may act to improve compliance among participant, and that, similar to other randomized controlled studies, the demonstrated high compliance figures do not reflect those of naturalistic "real life" drug administration.']	drug	CHEBI_EXT	[16994]	[16998]	PMC1481554_T139
PMC1481554	PMC1481554_113	[17063]	[17267]	['This did not reflect failure to take the two products but rather lack of motivation of healthy pregnant women to participate in this type of intensive protocol including daily diaries and returning pills.']	women	NCBITAXON_EXT	[17167]	[17172]	PMC1481554_T213
PMC1481554	PMC1481554_113	[17063]	[17267]	['This did not reflect failure to take the two products but rather lack of motivation of healthy pregnant women to participate in this type of intensive protocol including daily diaries and returning pills.']	women	UBERON_EXT	[17167]	[17172]	PMC1481554_T241
PMC1481554	PMC1481554_113	[17063]	[17267]	['This did not reflect failure to take the two products but rather lack of motivation of healthy pregnant women to participate in this type of intensive protocol including daily diaries and returning pills.']	pills	CHEBI_EXT	[17261]	[17266]	PMC1481554_T140
PMC1481554	PMC1481554_114	[17268]	[17363]	['However, because each woman served as her own control, the attrition does not bias the results.']	woman	NCBITAXON_EXT	[17290]	[17295]	PMC1481554_T214
PMC1481554	PMC1481554_114	[17268]	[17363]	['However, because each woman served as her own control, the attrition does not bias the results.']	woman	UBERON_EXT	[17290]	[17295]	PMC1481554_T242
PMC1481554	PMC1481554_115	[17364]	[17472]	['The women who dropped out were not different in their characteristics from those who completed the protocol.']	women	NCBITAXON_EXT	[17368]	[17373]	PMC1481554_T215
PMC1481554	PMC1481554_115	[17364]	[17472]	['The women who dropped out were not different in their characteristics from those who completed the protocol.']	women	UBERON_EXT	[17368]	[17373]	PMC1481554_T243
PMC1481554	PMC1481554_116	[17473]	[17685]	['Importantly, because compliance rate was an important endpoint we refrained from contacting the women to remind them of their participation, an act that could artificially affect compliance, with the medications.']	women	NCBITAXON_EXT	[17569]	[17574]	PMC1481554_T216
PMC1481554	PMC1481554_116	[17473]	[17685]	['Importantly, because compliance rate was an important endpoint we refrained from contacting the women to remind them of their participation, an act that could artificially affect compliance, with the medications.']	women	UBERON_EXT	[17569]	[17574]	PMC1481554_T244
PMC1481554	PMC1481554_116	[17473]	[17685]	['Importantly, because compliance rate was an important endpoint we refrained from contacting the women to remind them of their participation, an act that could artificially affect compliance, with the medications.']	medications	CHEBI_EXT	[17673]	[17684]	PMC1481554_T141
PMC1481554	PMC1481554_117	[17686]	[17877]	['Previous studies also reported on diarrhea occurring with micronutrients, however, in our study the occurrence of diarrhea was very rare and not different between the two study interventions.']	micronutrients	CHEBI_EXT	[17744]	[17758]	PMC1481554_T142
PMC1481554	PMC1481554_118	[17878]	[18196]	["Yet, this study, comparing tolerability and compliance rates between two prenatal micronutrient supplements different in their iron content and administration schedule, has identified several determinants of potential clinical significance, which may affect pregnant women's adherence to micronutrient supplementation."]	prenatal	GO_BP_EXT	[17951]	[17959]	PMC1481554_T193
PMC1481554	PMC1481554_118	[17878]	[18196]	["Yet, this study, comparing tolerability and compliance rates between two prenatal micronutrient supplements different in their iron content and administration schedule, has identified several determinants of potential clinical significance, which may affect pregnant women's adherence to micronutrient supplementation."]	micronutrient	CHEBI_EXT	[17960]	[17973]	PMC1481554_T143
PMC1481554	PMC1481554_118	[17878]	[18196]	["Yet, this study, comparing tolerability and compliance rates between two prenatal micronutrient supplements different in their iron content and administration schedule, has identified several determinants of potential clinical significance, which may affect pregnant women's adherence to micronutrient supplementation."]	iron	CHEBI_EXT	[18005]	[18009]	PMC1481554_T144
PMC1481554	PMC1481554_118	[17878]	[18196]	["Yet, this study, comparing tolerability and compliance rates between two prenatal micronutrient supplements different in their iron content and administration schedule, has identified several determinants of potential clinical significance, which may affect pregnant women's adherence to micronutrient supplementation."]	women	NCBITAXON_EXT	[18145]	[18150]	PMC1481554_T217
PMC1481554	PMC1481554_118	[17878]	[18196]	["Yet, this study, comparing tolerability and compliance rates between two prenatal micronutrient supplements different in their iron content and administration schedule, has identified several determinants of potential clinical significance, which may affect pregnant women's adherence to micronutrient supplementation."]	micronutrient	CHEBI_EXT	[18166]	[18179]	PMC1481554_T145
PMC1481554	PMC1481554_119	[18197]	[18371]	['A major problem in primary prevention of congenital anomalies by folic acid or folic acid containing micronutrients is the need to commence supplementation preconceptionally.']	folic acid	CHEBI_EXT	[18262]	[18272]	PMC1481554_T146
PMC1481554	PMC1481554_119	[18197]	[18371]	['A major problem in primary prevention of congenital anomalies by folic acid or folic acid containing micronutrients is the need to commence supplementation preconceptionally.']	folic acid	CHEBI_EXT	[18276]	[18286]	PMC1481554_T147
PMC1481554	PMC1481554_119	[18197]	[18371]	['A major problem in primary prevention of congenital anomalies by folic acid or folic acid containing micronutrients is the need to commence supplementation preconceptionally.']	micronutrients	CHEBI_EXT	[18298]	[18312]	PMC1481554_T148
PMC1481554	PMC1481554_119	[18197]	[18371]	['A major problem in primary prevention of congenital anomalies by folic acid or folic acid containing micronutrients is the need to commence supplementation preconceptionally.']	preconceptionally	GO_BP_EXT	[18353]	[18370]	PMC1481554_T194
PMC1481554	PMC1481554_120	[18372]	[18496]	['There is a serious and urgent need to educate potential parents to start such supplementation before pregnancy is confirmed.']	pregnancy	GO_BP_EXT	[18473]	[18482]	PMC1481554_T195
PMC1481554	PMC1481554_121	[18498]	[18680]	['Conclusion\nPregVit®, a supplement with lower iron content (35 mg), has significantly decreased constipation rates as compared to 60 mg iron- Materna and has similar compliance rates.']	iron	CHEBI_EXT	[18543]	[18547]	PMC1481554_T149
PMC1481554	PMC1481554_121	[18498]	[18680]	['Conclusion\nPregVit®, a supplement with lower iron content (35 mg), has significantly decreased constipation rates as compared to 60 mg iron- Materna and has similar compliance rates.']	iron	CHEBI_EXT	[18633]	[18637]	PMC1481554_T150
PMC1481554	PMC1481554_122	[18681]	[18775]	['High iron content in multivitamin supplements is associated with adverse effects in pregnancy.']	iron	CHEBI_EXT	[18686]	[18690]	PMC1481554_T151
PMC1481554	PMC1481554_122	[18681]	[18775]	['High iron content in multivitamin supplements is associated with adverse effects in pregnancy.']	multivitamin	CHEBI_EXT	[18702]	[18714]	PMC1481554_T152
PMC1481554	PMC1481554_122	[18681]	[18775]	['High iron content in multivitamin supplements is associated with adverse effects in pregnancy.']	pregnancy	GO_BP_EXT	[18765]	[18774]	PMC1481554_T196
